264 related articles for article (PubMed ID: 31569391)
21. XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a.
Wang J; Sun T; Meng Z; Wang L; Li M; Chen J; Qin T; Yu J; Zhang M; Bie Z; Dong Z; Jiang X; Lin L; Zhang C; Liu Z; Jiang R; Yang G; Li L; Zhang Y; Huang D
Cancer Lett; 2021 Apr; 503():197-212. PubMed ID: 33493586
[TBL] [Abstract][Full Text] [Related]
22. Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression.
Aboukameel A; Muqbil I; Baloglu E; Senapedis W; Landesman Y; Argueta C; Kauffman M; Chang H; Kashyap T; Shacham S; Neggers JE; Daelemans D; Heath EI; Azmi AS
Oncotarget; 2018 Oct; 9(82):35327-35342. PubMed ID: 30450161
[TBL] [Abstract][Full Text] [Related]
23. Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study.
London CA; Bernabe LF; Barnard S; Kisseberth WC; Borgatti A; Henson M; Wilson H; Jensen K; Ito D; Modiano JF; Bear MD; Pennell ML; Saint-Martin JR; McCauley D; Kauffman M; Shacham S
PLoS One; 2014; 9(2):e87585. PubMed ID: 24503695
[TBL] [Abstract][Full Text] [Related]
24. Selinexor, a novel selective inhibitor of nuclear export, reduces SARS-CoV-2 infection and protects the respiratory system in vivo.
Kashyap T; Murray J; Walker CJ; Chang H; Tamir S; Hou B; Shacham S; Kauffman MG; Tripp RA; Landesman Y
Antiviral Res; 2021 Aug; 192():105115. PubMed ID: 34157321
[TBL] [Abstract][Full Text] [Related]
25. Reversible disruption of XPO1-mediated nuclear export inhibits respiratory syncytial virus (RSV) replication.
Mathew C; Tamir S; Tripp RA; Ghildyal R
Sci Rep; 2021 Sep; 11(1):19223. PubMed ID: 34584169
[TBL] [Abstract][Full Text] [Related]
26. The past, present, and future of CRM1/XPO1 inhibitors.
Wang AY; Liu H
Stem Cell Investig; 2019; 6():6. PubMed ID: 30976603
[TBL] [Abstract][Full Text] [Related]
27. Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia.
Walker JS; Hing ZA; Harrington B; Baumhardt J; Ozer HG; Lehman A; Giacopelli B; Beaver L; Williams K; Skinner JN; Cempre CB; Sun Q; Shacham S; Stromberg BR; Summers MK; Abruzzo LV; Rassenti L; Kipps TJ; Parikh S; Kay NE; Rogers KA; Woyach JA; Coppola V; Chook YM; Oakes C; Byrd JC; Lapalombella R
J Hematol Oncol; 2021 Jan; 14(1):17. PubMed ID: 33451349
[TBL] [Abstract][Full Text] [Related]
28. Nuclear export mediated regulation of microRNAs: potential target for drug intervention.
Muqbil I; Bao B; Abou-Samra AB; Mohammad RM; Azmi AS
Curr Drug Targets; 2013 Sep; 14(10):1094-100. PubMed ID: 23834155
[TBL] [Abstract][Full Text] [Related]
29. The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review.
Landes JR; Moore SA; Bartley BR; Doan HQ; Rady PL; Tyring SK
J Cancer Res Clin Oncol; 2023 May; 149(5):2139-2155. PubMed ID: 35941226
[TBL] [Abstract][Full Text] [Related]
30. Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies.
Fischer MA; Friedlander SY; Arrate MP; Chang H; Gorska AE; Fuller LD; Ramsey HE; Kashyap T; Argueta C; Debler S; Byrne M; Villaume MT; Shaver AC; Senapedis W; Landesman Y; Baloglu E; Shacham S; Savona MR
Blood Adv; 2020 Feb; 4(3):586-598. PubMed ID: 32045477
[TBL] [Abstract][Full Text] [Related]
31. Selinexor: A First-in-Class Nuclear Export Inhibitor for Management of Multiply Relapsed Multiple Myeloma.
Peterson TJ; Orozco J; Buege M
Ann Pharmacother; 2020 Jun; 54(6):577-582. PubMed ID: 31793336
[No Abstract] [Full Text] [Related]
32. Combining selective inhibitors of nuclear export (SINEs) with chimeric antigen receptor (CAR) T cells for CD19‑positive malignancies.
Wang S; Sellner L; Wang L; Sauer T; Neuber B; Gong W; Stock S; Ni M; Yao H; Kleist C; Schmitt A; Müller-Tidow C; Schmitt M; Schubert ML
Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34165175
[TBL] [Abstract][Full Text] [Related]
33. Targeting XPO1-Dependent Nuclear Export in Cancer.
Kim E; Mordovkina DA; Sorokin A
Biochemistry (Mosc); 2022 Jan; 87(Suppl 1):S178-S70. PubMed ID: 35501995
[TBL] [Abstract][Full Text] [Related]
34. Chromosome Region Maintenance 1 (XPO1/CRM1) as an Anticancer Target and Discovery of Its Inhibitor.
Liu S; Qiao W; Sun Q; Luo Y
J Med Chem; 2021 Nov; 64(21):15534-15548. PubMed ID: 34669417
[TBL] [Abstract][Full Text] [Related]
35. Molecular profiling of anastatic cancer cells: potential role of the nuclear export pathway.
Seervi M; Sumi S; Chandrasekharan A; Sharma AK; SanthoshKumar TR
Cell Oncol (Dordr); 2019 Oct; 42(5):645-661. PubMed ID: 31147963
[TBL] [Abstract][Full Text] [Related]
36. Selective inhibition of nuclear export: a promising approach in the shifting treatment paradigms for hematological neoplasms.
Balasubramanian SK; Azmi AS; Maciejewski J
Leukemia; 2022 Mar; 36(3):601-612. PubMed ID: 35091658
[TBL] [Abstract][Full Text] [Related]
37. Leptomycin B inhibits the proliferation, migration, and invasion of cultured gastric carcinoma cells.
Zhu H; Yang Y; Wang L; Xu X; Wang T; Qian H
Biosci Biotechnol Biochem; 2020 Feb; 84(2):290-296. PubMed ID: 31619134
[TBL] [Abstract][Full Text] [Related]
38. Verdinexor, a Selective Inhibitor of Nuclear Exportin 1, Inhibits the Proliferation and Migration of Esophageal Cancer via XPO1/c-Myc/FOSL1 Axis.
Ou L; Wang X; Cheng S; Zhang M; Cui R; Hu C; Liu S; Tang Q; Peng Y; Chai R; Xie S; Wang S; Huang W; Wang X
Int J Biol Sci; 2022; 18(1):276-291. PubMed ID: 34975332
[TBL] [Abstract][Full Text] [Related]
39. Selinexor inhibits growth of patient derived chordomas
Walker CJ; Chang H; Henegar L; Kashyap T; Shacham S; Sommer J; Wick MJ; Levy J; Landesman Y
Front Oncol; 2022; 12():808021. PubMed ID: 36059685
[TBL] [Abstract][Full Text] [Related]
40. XPO1 Enables Adaptive Regulation of mRNA Export Required for Genotoxic Stress Tolerance in Cancer Cells.
Marullo R; Rutherford SC; Revuelta MV; Zamponi N; Culjkovic-Kraljacic B; Kotlov N; Di Siervi N; Lara-Garcia J; Allan JN; Ruan J; Furman RR; Chen Z; Shore TB; Phillips AA; Mayer S; Hsu J; van Besien K; Leonard JP; Borden KLB; Inghirami G; Martin P; Cerchietti L
Cancer Res; 2024 Jan; 84(1):101-117. PubMed ID: 37801604
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
